Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis

BACKGROUND: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib have both been proven effective for treating advanced non–small cell lung cancer (NSCLC), especially in East Asian patients. We conducted this meta-analysis to compare their efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenxiong, Wei, Yiping, Yu, Dongliang, Xu, Jianjun, Peng, Jinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090934/
https://www.ncbi.nlm.nih.gov/pubmed/30068310
http://dx.doi.org/10.1186/s12885-018-4685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090934/
https://www.ncbi.nlm.nih.gov/pubmed/30068310
http://dx.doi.org/10.1186/s12885-018-4685-y

Ejemplares similares